Related Experiment Video
Updated: Jun 19, 2025

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Identification and Validation of JAM-A as a Novel Prognostic and Immune Factor in Human Tumors
Tianyi Ren1,2, You Zheng2, Feichang Liu2,3
1Department of Oncology, Beijing Shijitan Hospital of Capital Medical University, Beijing 100038, China.
Abstract:
Junctional adhesion molecule-A (JAM-A), also known as F11 receptor (F11R), is a transmembrane glycoprotein that is involved in various biological processes, including cancer initiation and progression. However, the functional characteristics and significance of JAM-A in pan-cancer remain unexplored. In this study, we used multiple databases to gain a comprehensive understanding of JAM-A in human cancers. JAM-A was widely expressed in various tissues, mainly located on the microtubules and cell junctions. Aberrant expression of JAM-A was detected in multiple cancers at both mRNA and protein levels, which can be correlated with poorer prognosis and may be attributed to genetic alterations and down-regulated DNA methylation. JAM-A expression was also associated with immune infiltration and may affect immunotherapy responses in several cancers. Functional enrichment analysis indicated that JAM-A participated in tight junction and cancer-related pathways. In vitro experiments verified that JAM-A knockdown suppressed the proliferation and migration abilities of breast cancer cells and liver cancer cells. Overall, our study suggests that JAM-A is a pan-cancer regulator and a potential biomarker for predicting prognosis and immune-therapeutic responses for different tumors.
Related Concept Videos
Tumor Immunotherapy
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The JAK-STAT Signaling Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...

